ArticleMolecular biology reports2025
Modulation of inflammatory and cuproptotic crosstalk by Ethyl and propyl gallate: a multi-targeted strategy against experimental colitis.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
objectiveUlcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by oxidative stress, immune dysregulation, and epithelial barrier dysfunction. This study investigated the protective effects of two phenolic antioxidants derived from food sources, ethyl gallate (EG) and propyl gallate (PG), in conjunction with copper-enriched water, against dextran sulfate sodium (DSS)-induced colonic injury in mice. The focus was on the modulation of inflammation, oxidative stress, apoptosis, and the novel regulatory pathway of cuproptosis.
methodThe experimental protocol entailed the induction of colitis through the administration of 2.5% DSS in drinking water over a period of seven days, along with oral administration of EG, PG, or their combination at a dosage of 50 mg/kg for 21 days. Cytokine levels were quantified using ELISA, while qPCR and western blotting were employed to analyze inflammatory markers (NF-κB, JAK2-STAT3), oxidative markers (Nrf2/HO-1), apoptotic markers (Bcl2/Bax), and cuproptotic markers (FDX1/DLAT). The TUNEL assay was used to evaluate apoptotic cell death.
resultsEG and PG significantly reduced the levels of TNF-α, IL-1β, and IL-6 by inhibiting the NF-κB and JAK-STAT signalling pathways while concurrently increasing the levels of IL-37. Oxidative stress is alleviated through activation of the Nrf2/HO-1 pathway. Apoptosis was suppressed via upregulation of Bcl-2/Bcl-XL and downregulation of BAX, as corroborated by the TUNEL assay results. Additionally, EG and PG mitigated cuproptosis by decreasing the expression of FDX1, DLAT, and LIAS, thereby maintaining intestinal barrier integrity.
conclusionThe observations presented herein offer significant mechanistic insights into the role of ethyl gallate (EG) and propyl gallate (PG), in conjunction with copper-enriched water, in the management of ulcerative colitis through the modulation of inflammatory, oxidative, apoptotic, and cuproptotic pathways. Notably, this study is the first to document the effects of EG and PG on cuproptosis-related proteins and their potential role in alleviating DSS-induced colonic toxicity, thereby supporting further investigation of their application as food-based therapeutic agents for intestinal disorders.
Indexed as
Identifiers
41085583What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.